Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Market Closed - BME
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
2 EUR +0.91% Intraday chart for Oryzon Genomics S.A. +5.60% +5.93%
Apr. 22 Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat CI
Apr. 08 ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORY Stock
  4. News Oryzon Genomics S.A.
  5. Analyst Reco.